Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.16 USD
Change Today +0.01 / 0.11%
Volume 544.0K
SGMO On Other Exchanges
SGMO is not on other exchanges.
As of 5:20 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

sangamo biosciences inc (SGMO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $19.25
52 Week Low
07/27/15 - $8.57
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sangamo biosciences inc (SGMO) Related Businessweek News

No Related Businessweek News Found

sangamo biosciences inc (SGMO) Details

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. Its proprietary zinc finger DNA-binding protein (ZFP) technology enables precise and highly specific genome modification and gene regulation. The company’s ZFPs can be linked to functional domains that regulate gene expression to create ZFP transcription factors (ZFP TFs) capable of activating or repressing a targeted gene. The ZFPs can also be linked to endonuclease domains to create zinc finger nucleases (ZFNs), which enable precise genome editing to facilitate the disruption of a specific gene or the targeted addition of a new gene or DNA sequence into the genome cells, without the detrimental consequences of off-target DNA binding activity. The Company’s lead ZFP Therapeutic candidate is SB-728-T, a ZFN-mediated autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS). Sangamo BioSciences also has proprietary preclinical stage ZFP Therapeutic programs for lysosomal storage disorders such as Hunter and Hurler syndromes. In addition, the company has preclinical programs in hemophilia A and B, and Huntington’s disease in collaboration with Shire International GmbH; and hemoglobinopathies, such as beta-thalassemia and sickle cell disease in collaboration with Biogen Inc. Sangamo also has strategic partnerships with Sigma-Aldrich Corporation; Dow AgroSciences, LLC; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd; and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.

102 Employees
Last Reported Date: 02/25/15
Founded in 1995

sangamo biosciences inc (SGMO) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $650.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $405.0K
Chief Medical Officer and Vice President of T...
Total Annual Compensation: $440.0K
Executive Vice President of Research and Deve...
Total Annual Compensation: $460.0K
Compensation as of Fiscal Year 2014.

sangamo biosciences inc (SGMO) Key Developments

Sangamo Biosciences Inc. Announces Resignation of Philip D.Gregory as Senior Vice President, Research and Chief Scientific Officer

On May 29, 2015, Philip D.Gregory, senior vice president, research and chief scientific officer, resigned from Sangamo BioSciences Inc. Gregory's responsibilities are being assumed by other vice presidents in the research group, who will now report to Geoff Nichol, executive vice president, research and development.

Sangamo Announces Encouraging Data from Lysosomal Storage Disorders Study

Sangamo BioSciences Inc. has announced encouraging data from its proprietary ZFP Therapeutic programs in disease models of lysosomal storage disorders, or LSDs. The data demonstrated durable expression of levels of functional enzyme sufficient to correct biomarkers of disease in mouse models of Hunter and Hurler syndromes, enabled by Sangamo's zinc finger nuclease (ZFN)-mediated genome editing technology. The LSD programs are part of Sangamo's In Vivo Protein Replacement Platform (IVPRP) portfolio of ZFP Therapeutics. The IVPRP uses ZFN-mediated genome editing to precisely insert disease-corrective genes into the albumin locus in the genome of liver cells. The correct version of the enzyme, which is defective in a genetic disease, is then made by the powerful machinery that normally drives albumin expression, leading to the production and secretion of the missing enzyme by the liver. A significant and sustained reduction in glycosaminoglycan (GAG) levels (a biomarker of lysosomal storage disorder progression) was observed in the urine and secondary tissue (liver, spleen, kidneys and lungs) in Hurler and Hunter mice 21 days post treatment with ZFNs. The accumulation of GAG oligosaccharides in the lysosomes of cells leads to dysfunction in several tissues throughout the body and is associated with symptoms of these LSDs. Production of the corrective enzyme was also shown to be durable through the twelve week study, consistent with earlier studies of the IVPRP for clotting factor, Factor IX, which demonstrated sustained production for over a year. The data also demonstrated that in models of Hurler and Hunter syndrome, high levels of human IDUA (hIDUA) and human IDS (hIDS) enzyme activity respectively, could be detected in the liver (site of expression) and plasma of treated animals. In addition, functional enzymes could be detected in secondary tissues such as the spleen, kidneys, and lungs, demonstrating that they had been taken up into these tissues from the circulation.

Sangamo Biosciences Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 01:30 PM

Sangamo Biosciences Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Edward O. Lanphier, Founder, Chief Executive Officer, President, Director and Member of Clinical Review Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGMO:US $9.16 USD +0.01

SGMO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bluebird Bio Inc $164.60 USD -1.23
Cellectis SA €32.40 EUR -0.17
Fibrocell Science Inc $6.89 USD +0.37
Spark Therapeutics Inc $62.70 USD +1.26
uniQure NV $26.47 USD +0.72
View Industry Companies

Industry Analysis


Industry Average

Valuation SGMO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.4x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANGAMO BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at